Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the ARAMIS phase III clinical trial presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.
Sponsored Story
By StoryStudio April 1, 2021 4:35 pm
(BPT) – In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in
Posted Monday, February 22, 2021 10:01 am
(BPT) - In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in